High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia

Leukemia Research

Volumn 38, Issue 1, 2014, Pages 65-70

  Ko, Sun Young ^a   Park, Chan Jeoung ^b   Park, Sang Hyuk ^b   Cho, Young Uk ^b   Jang, Seongsoo ^b   Seo, Eul ju ^b   Kim, Nayoung ^c   Kim, Dae Young ^b   Koh, Kyung Nam ^b   Im, Ho Joon ^b   Seo, Jong Jin ^b   Chi, Hyun Sook ^b  

^a Korea University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

Acute lymphoblastic leukemia; Adult; CXCR4; Prognostic marker; Survival; VLA 4

Indexed keywords

ASPARAGINASE; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; PREDNISOLONE; VERY LATE ACTIVATION ANTIGEN 4; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; DISEASE FREE SURVIVAL; HUMAN; IMMUNOPHENOTYPING; INFANT; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SURVIVAL RATE; VERY ELDERLY;

EID: 84890559947     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.10.016     Document Type: Article

References (20)

1. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166-178.
2. Thomas X., Boiron J.M., Huguet F., Dombret H., Bradstock K., Vey N., et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004, 22:4075-4086.
3. Bradstock K., Bianchi A., Makrynikola V., Filshie R., Gottlieb D. Long-term survival and proliferation of precursor-B acute lymphoblastic leukemia cells on human bone marrow stroma. Leukemia 1996, 10:813-820.
4. Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011, 29:591-599.
5. Ponomaryov T., Peled A., Petit I., Taichman R.S., Habler L., Sandbank J., et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000, 106:1331-1339.
6. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
7. Burger J.A., Spoo A., Dwenger A., Burger M., Behringer D. CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol 2003, 122:579-589.
8. Rombouts E.J., Pavic B., Löwenberg B., Ploemacher R.E. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004, 104:550-557.
9. Spoo A.C., Lübbert M., Wierda W.G., Burger J.A. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007, 109:786-791.
10. Konoplev S., Rassidakis G.Z., Estey E., Kantarjian H., Liakou C.I., Huang X., et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007, 109:1152-1156.
11. Tavernier-Tardy E., Cornillon J., Campos L., Flandrin P., Duval A., Nadal N., et al. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res 2009, 33:764-768.
12. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9:1158-1165.
13. Becker P.S., Kopecky K.J., Wilks A.N., Chien S., Harlan J.M., Willman C.L., et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 2009, 113:866-874.
14. Walter R.B., Alonzo T.A., Gerbing R.B., Ho P.A., Smith F.O., Raimondi S.C., et al. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol 2010, 28:2831-2838.
15. Konoplev S., Jorgensen J.L., Thomas D.A., Lin E., Burger J., Kantarjian H.M., et al. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer 2011, 117:4689-4695.
16. Shalapour S., Hof J., Kirschner-Schwabe R., Bastian L., Eckert C., Prada J., et al. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica 2011, 96:1627-1635.
17. Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995, 9:1783-1786.
18. Crazzolara R., Kreczy A., Mann G., Heitger A., Eibl G., Fink F.M., et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol 2001, 115:545-553.
19. Schneider P., Vasse M., Al Bayati A., Lenormand B., Vannier J.P. Is high expression of the chemokine receptor CXCR-4 of predictive value for early relapse in childhood acute lymphoblastic leukaemia. Br J Haematol 2002, 119:579-580.
20. Hafez M., Al-Tonbary Y., El-Bayoumi M.A., Hatem N., Hawas S., Mansour A., et al. Markers of apoptosis and proliferation related gene products as predictors of treatment outcome in childhood acute lymphoblastic leukemia. Hematology 2007, 12:209-218.